Online first
Clinical vignette
Published online: 2025-02-27
Recurrent glioblastoma: a typical example of a complex approach
Abstract
Not required for Clinical Vignette.
Keywords: glioblastomarelapsere-irradiation
References
- Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015; 152: 63–82.
- Cantidio FS, Gil GO, Queiroz IN, et al. Glioblastoma - treatment and obstacles. Rep Pract Oncol Radiother. 2022; 27(4): 744–753.
- Śledzińska P, Bebyn MG, Furtak J, et al. Prognostic and Predictive Biomarkers in Gliomas. Int J Mol Sci. 2021; 22(19).
- Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997–1003.
- Huang B, Yu Z, Liang R. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival. BMC Neurol. 2021; 21(1): 424.
- Tsien CI, Pugh SL, Dicker AP, et al. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023; 41(6): 1285–1295.
- Minniti G, Niyazi M, Alongi F, et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021; 16(1): 36.
- Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022; 23(1): 53–64.